GFP/Luc Reporter Cell Line - ES-2

The ES-2 cell line is a well-established human model of ovarian clear cell carcinoma, originally derived from a surgical tumor specimen of a 47-year-old patient. Recognized for its aggressive growth profile, fibroblastic morphology, and inherent resistance to several standard chemotherapeutic agents such as cisplatin, it serves as a critical preclinical tool for studying refractory and difficult-to-treat ovarian cancers. The GFP/Luc Reporter Cell Line - ES-2 is a stably transfected, advanced derivative explicitly engineered to co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct guarantees steady, high-level expression of both reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental biological characteristics, distinct mutational profile, or intrinsic tumorigenic potential of the original parental ES-2 cells.

The incorporation of these dual reporter genes significantly broadens the experimental utility of the ES-2 model for translational gynecological oncology. In vitro, the bright GFP fluorescence allows researchers to easily visualize cellular dynamics, quantify proliferation rates, and seamlessly isolate specific cell populations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase expression serves as the foundation for non-invasive, longitudinal tracking of tumor progression through bioluminescence imaging (BLI). As a human-derived cell line, the ES-2-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish highly aggressive subcutaneous or intraperitoneal xenografts. This makes the reporter line exceptionally well-suited for modeling the peritoneal dissemination characteristic of advanced ovarian cancer. It is an invaluable platform for evaluating the in vivo efficacy of novel targeted therapies, overcoming chemoresistance, and testing emerging biotherapeutics, facilitating the real-time quantification of localized tumor burden and metastatic spread in living subjects.